Back to Search
Start Over
The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission
- Source :
- Leukemia & Lymphoma. 60:3099-3101
- Publication Year :
- 2019
- Publisher :
- Informa UK Limited, 2019.
-
Abstract
- Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) and changed it from a fatal disease to a chronic illness. The goals of treatment are no longer survival but have...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Treatment outcome
Fusion Proteins, bcr-abl
03 medical and health sciences
Myelogenous
chemistry.chemical_compound
0302 clinical medicine
Risk Factors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
hemic and lymphatic diseases
Internal medicine
medicine
Humans
skin and connective tissue diseases
Protein Kinase Inhibitors
Dose-Response Relationship, Drug
business.industry
Ponatinib
Imidazoles
Myeloid leukemia
Hematology
medicine.disease
humanities
respiratory tract diseases
Pyridazines
Leukemia
Treatment Outcome
chemistry
Cardiovascular Diseases
030220 oncology & carcinogenesis
Mutation
Fatal disease
sense organs
business
Tyrosine kinase
030215 immunology
Subjects
Details
- ISSN :
- 10292403 and 10428194
- Volume :
- 60
- Database :
- OpenAIRE
- Journal :
- Leukemia & Lymphoma
- Accession number :
- edsair.doi.dedup.....3807625c5b917cf28a32f5438f4e990e